Skip to content

View Spec Sheet

open_in_new
  1. Shop all
  2. Monoclonal

A26550

ABflo[R] 450 Rabbit anti-Human CD152/CTLA-4 monoclonal antibody

Size

POA

SKU:
A26550
Additional Names:
ALPS5|CD|CD152|CELIAC3|CTLA-4|GRD4|GSE|IDDM12
Application:
Flow Cytometry
Species Reactivity:
Human
Purification:
Affinity Purified
Storage Conditions:
2-8[o]C Avoid freeze/thaw cycles.
Supplier:
Abclonal
Host:
Rabbit
Reactivities:
Human
Immunogen:
Recombinant protein (or fragment).This information is considered to be commercially sensitive.
Formulation:
Unmodified
Uniprot:
P16410
Synonyms:
ALPS5;CD;CD152;celiac disease 3;CELIAC3;CTLA-4;cytotoxic T lymphocyte associated antigen 4 short spliced form;cytotoxic T-lymphocyte protein 4;Cytotoxic T-lymphocyte-associated antigen 4;cytotoxic T-lymphocyte-associated serine esterase-4;GRD4;GSE;IDDM12;insulin-dependent diabetes mellitus 12;ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Extra Details:
Cytotoxic T-lymphocyte protein 4 (CTLA-4, CD152) is a member of the immunoglobulin superfamily that negatively regulates early T-cell activation. This protein is primarily expressed on T cells, including CD8+ cytotoxic T cells, CD4+ helper T cells, and CD4+/FoxP3+ regulatory T cells (Tregs). On the cell surface, CTLA-4 competes with CD28 for binding to the ligands B7.1 (CD80) and B7.2 (CD86), thereby downregulating T-cell activity. The subsequent activation of downstream effectors SHP-2 and PP2A attenuates TCR signaling. Studies have shown that CTLA-4 gene knockout mice develop severe lymphoproliferative disorders and die at an early age, confirming the essential role of CTLA-4 as a negative regulator of T cells. Correspondingly, mutations in the CTLA4 gene are associated with various autoimmune and immune dysregulation syndromes, including insulin-dependent diabetes mellitus, Graves' disease, Hashimoto's thyroiditis, celiac disease, systemic lupus erythematosus, and autoimmune lymphoproliferative syndrome type V. Further research has established that blockade of the CTLA-4 pathway represents an effective strategy in cancer immunotherapy.
Shipping Conditions:
Blue Ice